Paper · 24253418

First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.

Iacovelli R and 3 others. Cancer Biol Ther, 2014. Cited by 7 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. Papers, record 24253418. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24253418

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile.; PubMed
Journal: Cancer Biol Ther; PubMed
Year: 2014; PubMed
Publication types: Journal Article, Comment; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/24253418/; PubMed
DOI: https://doi.org/10.4161/cbt.27150; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC3938518/; PubMed
The journal: https://conductscience.org/library/journal-index/101137842; PubMed
Citations, by iCite: 7; iCite
Relative citation ratio, by iCite: 0.19; iCite
Revised in PubMed: 2021-10-21; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Iacovelli R	Roberto
2	Verzoni E	Elena
3	De Braud F	Filippo
4	Procopio G	Giuseppe

Source PubMed

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Angiogenesis Inhibitors	Major topic
Carcinoma, Renal Cell	Major topic
Indoles	Major topic
Kidney Neoplasms	Major topic
Pyrimidines	Major topic
Pyrroles	Major topic
Sulfonamides	Major topic
Female
Humans
Male

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

Kind	PMID	Title	In Papers
Comment on	23,964,934	Pazopanib versus sunitinib in metastatic renal-cell carcinoma.	https://conductscience.org/library/papers/23964934

Source PubMed

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	11,306,510	Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.	Cancer Res	2001	https://conductscience.org/library/papers/11306510	PubMed
2	20,100,962	Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.	J Clin Oncol	2010	https://conductscience.org/library/papers/20100962	PubMed
3	19,615,940	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.	Lancet Oncol	2009	https://conductscience.org/library/papers/19615940	PubMed
4	17,215,529	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.	N Engl J Med	2007	https://conductscience.org/library/papers/17215529	PubMed
5	20,384,576	Past, present and future of targeted therapy in solid tumors.	Curr Cancer Drug Targets	2010	https://conductscience.org/library/papers/20384576	PubMed
6	23,485,231	Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.	Eur J Cancer	2013	https://conductscience.org/library/papers/23485231	PubMed
7	23,964,934	Pazopanib versus sunitinib in metastatic renal-cell carcinoma.	N Engl J Med	2013	https://conductscience.org/library/papers/23964934	PubMed
8	23,981,115	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.	Br J Clin Pharmacol	2014	https://conductscience.org/library/papers/23981115	PubMed
9	10,561,319	Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.	J Clin Oncol	1999	https://conductscience.org/library/papers/10561319	PubMed
10	19,826,129	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.	J Clin Oncol	2009	https://conductscience.org/library/papers/19826129	PubMed

1 to 10 of 12

See all 12 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMID	Title	Journal	Year	In Papers	Source
35,557,976	Key Prognostic Value of Lysosomal Protein Transmembrane 5 in Kidney Renal Clear Cell Carcinoma.	Int J Gen Med	2022	https://conductscience.org/library/papers/35557976	PubMed
28,664,385	Pazopanib: a Review in Advanced Renal Cell Carcinoma.	Target Oncol	2017	https://conductscience.org/library/papers/28664385	PubMed
26,251,610	Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement.	J Multidiscip Healthc	2015	https://conductscience.org/library/papers/26251610	PubMed
25,866,016	Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.	Cancer Biol Ther	2015	https://conductscience.org/library/papers/25866016	PubMed
24,556,916	Pazopanib and HDAC inhibitors interact to kill sarcoma cells.	Cancer Biol Ther	2014	https://conductscience.org/library/papers/24556916	PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24253418

GET https://conductscience.org/api/papers/v1/24253418/authors

API reference For AI assistants